Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmaceutics
Hlavní autoři: Berdugo, Marianne, Delaunay, Kimberley, Lebon, Cécile, Naud, Marie-Christine, Radet, Lolita, Zennaro, Léa, Picard, Emilie, Daruich, Alejandra, Beltrand, Jacques, Kermorvant-Duchemin, Elsa, Polak, Michel, Crisanti, Patricia, Behar-Cohen, Francine F.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8308933/
https://ncbi.nlm.nih.gov/pubmed/34371786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13071095
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky